MedTrace Logo

Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia

NCT01174043 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2023-10-13

Study results available
· View outcomes & findings →

Summary

This research study is looking for patients with newly diagnosed acute myeloid leukemia (AML), AML that has returned (relapsed), or it has not responded adequately to previous treatments. Treating certain patients with chemotherapy may not be to their benefit or may cause more harm than benefit. The purpose of this study is to find out what effects (good and bad) erlotinib has on patients and their AML.

Conditions

  • Leukemia, Myelomonocytic, Acute

Interventions

DRUG

Erlotinib

Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.

Sponsors & Collaborators

  • OSI Pharmaceuticals

    collaborator INDUSTRY

  • Indiana University

    lead OTHER

Principal Investigators

  • S. Hamid Sayar, MD · Indiana University Melvin and Bren Simon Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01174043 on ClinicalTrials.gov